April 25, 2023 - FDA Approves Tofersen

Tofersen, a drug pioneered by Dr. Smith alongside Ionis Pharmaceuticals (Frank Bennett), and UCSD (Don Cleveland), was approved by the FDA for the treatment of one form of familial ALS. The approval of Tofersen is not only a milestone in the history of ALS, but also a milestone for the Center which has now been involved in the development of 2 out of the 5 drugs available for ALS.

Pictured above is the UCSD and CNS SOD1 Antisense team. Not pictured: Dr. Bennett (Ionis Pharmaceuticals). From left to right: Tim Miller, Dr. Smith, Don Cleveland, Melissa McAlonis-Downes.

Above is an early photo of the antisense team that was taken outside of Ionis's original laboratory in Carlsbad. Pictured from left to right: Tim Miller, Don Cleveland, Brett Monia, Tom Condon, Dr. Smith, Frank Bennett.

https://alsagoldenwest.org/fda-approves-treatment-of-als-associated-with-a-mutation-in-the-sod1-gene/

https://investors.biogen.com/news-releases/news-release-details/fda-grants-accelerated-approval-qalsodytm-tofersen-sod1-als#:~:text=for%20Alerts%20Search-,FDA%20Grants%20Accelerated%20Approval%20for%20QALSODY%E2%84%A2%20(tofersen)%20for%20SOD1,a%20Genetic%20Cause%20of%20ALS&text=CAMBRIDGE%2C%20Mass.%2C%20April%2025,GLOBE%20NEWSWIRE)%20%2D%2D%20Biogen%20Inc.

December 19, 2022 - "Pathogenesis of Alzheimer's Disease: Involvement of the Choroid Plexus"

Alzheimers & Dementia: The Journal of the Alzheimer's Association has accepted "Pathogenesis of Alzheimer's Disease: Involvement of the Choroid Plexus" for publication. This paper is further support for a novel idea proposed by Dr. Smith and his colleagues that was published in 2019.

A New Patent for CNS

The United States Patent and Trademark Office has notified CNS that they will be issued a patent on December 27th, 2022, for several unique pharmaceuticals which we believe will be useful for treating neurodegenerative diseases.